Instructions for making a CLIPS Card:PREVENTION

Slides:

Advertisements

Similar presentations

TREATING LIPIDS FOR PREVENTION OF CAD : HOW AGGRESSIVE SHOULD WE BE? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration.

Advertisements

Summary Prepared by Melvyn Rubenfire, MD

Lipid Management in 2015: Risk & Controversies

The Risk Concept in health care Definition of a risk factor  a disease precursor associated with a higher than average morbidity or mortality rate. John.

10 Points to Remember on Lifestyle Management to Reduce Cardiovascular RiskLifestyle Management to Reduce Cardiovascular Risk Summary Prepared by Elizabeth.

CVD risk estimation and prevention: An overview of SIGN 97.

Presenter Disclosure Information Paul M Ridker, MD, FACC Dr Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.

Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

Understanding blood lipids and glucose How a Healthy Lifestyle can improve your numbers Susan Fullmer, PhD RD Associate Teaching Professor Nutrition, Dietetics,

LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]

DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.

EHRS as a Tool to Improve BP Control 1.Brief history of OQIUN, CCI. Began 1999 using data cards. Started working with multiple practice sites using different.

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?

Risk estimation and the prevention of cardiovascular disease SIGN 97.

Metabolic Syndrome Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD.

CHRISTIAN SONNIER MD 7/15/14 Hyperlipidemia:. Hyperlipidemia Definition: an elevation of total cholesterol and or LDL with or without decrease in HDL.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

VA National Center for Health Promotion and Disease Prevention Using USPSTF Recommendations in VHA Clinical Practice Linda Kinsinger, MD, MPH Chief Consultant.

Self-Management Support Strategies for Improving your Patients’ CVD Risk Bonnie Jortberg PhD, RD, CDE Robyn Wearner RD, MA Department of Family Medicine.

ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines

CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.

PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.

How Do We Individualize Guidelines in an Era of Personalized Medicine? Douglas K. Owens, MD, MS VA Palo Alto Health Care System Stanford University, Stanford.

Yusra Mir, MD Zunairah Syed, MD Harjagjit Maan, MD

Primary Prevention of Cardiovascular Disease (CVD) Events with Statins

Mini-Lecture Michelle Di Fiore Revised 4/2017

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Figure 1: Questions included in questionnaire

Dyslipidemia and Primary Prevention

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Cholesterol practice questions

Instructions for making a CLIPS Card:PREVENTION

The Latest Lipid Guidelines:

Diabetes Health Status Report

Updates and Perspectives in Diabetic Dyslipidemia

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Statin Selection in the Elderly

Repeat fasting lipid profile to confirm in 1-2 weeks

Neil J. Stone et al. JACC 2014;63:

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Obesity and Dyslipidemia: How Would You Treat?

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

New Pathways in Lipid Care

RCHC’s Cardiovascular Health Initiative

Martin Bødtker Mortensen, and Erling Falk JACC 2018;71:85-94

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

ASPIRE Workshop 1: Conceiving the Research Idea

Rational Order of Laboratory Tests in Cardiovascular Diseases

Instructions for making a CLIPS Card:PREVENTION

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Contemporary Evidence-Based Guidelines

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.

Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.

Goals & Guidelines A summary of international guidelines for CHD

Train-the-Trainer Cases

Omega-3s vs Pure EPA in Clinical Practice

Train-the-Trainer Cases

Train-the-Trainer Cases

Section 6: Update on lipid treatment guidelines

Shared-Decision Making in Dyslipidemia

Stroke Prevention: An Evidence-Based Update

QRISK 3 – Clare Hawley - Summary slide

Presentation transcript:

Instructions for making a CLIPS Card:PREVENTION Use this 2 slide Powerpoint template following this intro slide to create the 2-sided CLIP session card you are working on. Remove this slide and email the finished product with 2 slides (front and back) to Cristina at vallejc1@sutterhealth.org Name the presentation “CLIPS TOPIC NAME YEAR MADE” e.g. “CLIPS LIPID SCREENING 2015” Each card should take about 15 minutes to present/ask/discuss. Try wherever possible to include the name of the organization that makes the screening recommendation, NNT for screening Include information about important safety net programs where relevant: FPACT, CDP, BCCCP/BCCTP, low cost pharmacy programs, community resources, common barriers

Screening for Lipid Disorders (1) C.L.I.P.S. Why do we screen? Treatment of HLD with statins reduces the risk of heart attack and stroke, absolute risk reduction depends on the level of risk at start Primary Prevention (those with no known CVD) Women >45 (A) Women 20-44 with risk factors (B) Men >35 (A) Men 20-24 with risk factors (B) Risk Factors include: HTN, Obesity, Tobacco, FHx, DM Interval for screening: q 5 years, sooner if high/borderline results Age to stop screening: not established, over 65: consider if never screened, other risk factors present(see above) Who makes these recommendation? USPSTF 2008 How do we screen ICD code has to be a condition or risk factor not V code In eCW, order “Lipid panel with reflex to direct LDL” non-fasting Order a follow up fasting test if TG were significantly elevated Clinical care tools for point of care AHRQ ePSS App (USPSTF guidelines) ASCVD Risk Calculator (Based on 2013 ACC/AHA guidelines) Algorhythym for treatment by AHA 2013 Consider asking if anyone has/uses these APPS What is the relative risk reduction of statins for primary prevention of CVD event? About 30% (an at-best estimate) Updated 5/15 T.Scott

Screening for Lipid Disorders (2) C.L.I.P.S. How do you interpret the results? LDL-C >190 or TG >500 start high intensity statin all ages LDL-C 70-189 with no DM, CAD, ASCVD Risk >7.5% moderate to high intensity statin This is displayed in the treatment algorhythm (make available) Put this algorhythm in favorites on the internet Interventions to reduce risk of CVD event Smoking cessation Exercise Dietary change: healthy oils and fats, fewer refined carbohydrates High-intensity statins: Partnership: Atorva 40-80*, Rosuvastatin (STEP) Target/Walmart: none available at high intensity SRCHC: none available at high intensity Moderate-intensity statins: Partnership: Atorva 10-20* Target/Walmart: Lova 40 SRCHC: Prava 40,Simva 20-40 Considerations for population management: PHP: What high- intensity statin is available through a $4 or low cost program? none